JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
A phase 1/2 trial of JAB-2485 (Aurora A inhibitor) in triple-negative breast cancer and small-cell lung cancer, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.
Overview
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05490472 by Jacobio Pharmaceuticals Co., Ltd., with 102 participants planned, started 2022-12-20 and due to reach its primary completion in 2026-08. Interventions recorded: JAB-2485 (Aurora A inhibitor).
Similar pages
not linked directly; found by shared links- TrialA First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Shares Jacobio Pharmaceuticals, Small-cell lung cancer and the tag pipeline.
- TrialJAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialA Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialJAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialStudy of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialFirst in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Shares Triple-negative breast cancer (TNBC), Small-cell lung cancer and the tag pipeline.
- TrialProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.